Testosterone Therapy Is Surging: What the TRAVERSE Trial Says About Heart Risk

Testosterone therapy has moved from fringe to mainstream. Prescriptions climbed sharply after a 2023 trial eased decades of cardiovascular fear, and 2026 guidance continues to refine who should take it. The story is no longer "does it kill your heart," but "who actually benefits, and what do we still watch for."

Key Takeaways

• The TRAVERSE trial (NEJM, 2023) found testosterone replacement was noninferior to placebo for major adverse cardiac events in men with hypogonadism and high cardiovascular risk.
• It did show higher rates of atrial fibrillation, acute kidney injury, and a trend toward more venous clots, so monitoring matters.
• Therapy is intended for men with confirmed low testosterone and symptoms, not for age-related decline alone.
• A 2026 European expert panel reaffirmed that, used selectively and monitored, testosterone is cardiovascularly safe for appropriate patients.

What Did the TRAVERSE Trial Actually Find?

TRAVERSE enrolled 5,246 men aged 45 to 80 with low testosterone and either preexisting cardiovascular disease or multiple risk factors (Lincoff et al., NEJM, 2023). The primary result: testosterone gel was noninferior to placebo for the composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke, with a hazard ratio of 0.96.

The point estimate actually favored testosterone slightly, though not significantly. That result ended a long standoff rooted in flawed observational studies from 2013 to 2014 that had triggered an FDA warning and a prescription collapse.

Citation capsule: In TRAVERSE, a randomized trial of 5,246 men with hypogonadism and cardiovascular risk, testosterone replacement did not increase major adverse cardiac events compared with placebo (HR 0.96, 95% CI 0.78 to 1.17), meeting noninferiority, while atrial fibrillation and acute kidney injury occurred more often in the treatment group (Lincoff et al., NEJM, 2023).

This aligns with our CKM syndrome guideline coverage, which emphasizes treating metabolic and cardiovascular risk together rather than in isolation.

What Are the Real Remaining Risks?

The trial was not risk-free. Atrial fibrillation was more common (about 3.5% versus 2.4%), as was acute kidney injury, and there was a nonsignificant trend toward more pulmonary embolism (studiesuggest reporting, 2023 to 2026). A 2026 European expert panel noted these signals and stressed regular monitoring, especially of hematocrit (Zitzmann et al., Andrology, 2026).

So the modern answer is not "perfectly safe for all," but "safe for selected patients with follow-up." Our blood pressure medication timing guide reflects the same monitoring discipline.

Who Should Actually Take It?

Appropriate candidates are men with consistently low testosterone on repeat testing plus symptoms such as low libido, fatigue, reduced muscle mass, or mood change. It is not intended for men whose levels are merely on the low end of normal due to aging, a point Endocrine Society guidance has long stressed.

Because testosterone can affect fertility and prostate markers, a clinician workup precedes therapy. Our pharmacist interaction guide covers how to get that review.

Why the Recent Surge?

Cleared cardiovascular fears, direct-to-consumer clinics, and growing interest in healthy aging all pushed prescribing up. The risk is that enthusiasm outruns evidence, with men seeking therapy for fatigue that has other causes.

Targeted use, confirmed deficiency, and monitoring are the guardrails. Our wasting money on supplements guide makes a similar point about chasing vitality through unproven products.

Frequently Asked Questions

Does testosterone cause heart attacks?

The large randomized TRAVERSE trial found no increase in major cardiac events versus placebo (NEJM, 2023).

What should be monitored?

Hematocrit, blood pressure, kidney function, and prostate markers, with periodic symptom and level checks.

Is it for low libido alone?

Only when low testosterone is confirmed; many other causes of low libido exist.

Can I buy it online safely?

Use a licensed clinician who orders tests and monitors; avoid unverified telehealth sources.

Conclusion

Testosterone therapy is no longer the cardiac pariah it was a decade ago. TRAVERSE showed it does not raise heart-attack or stroke risk in appropriate patients, while flagging atrial fibrillation and kidney signals to watch. The win is selective use with real testing and monitoring, not blanket treatment of normal aging.

Cluster: This article belongs to our men's health and cardiometabolic cluster. Read CKM syndrome 2026 guideline, blood pressure meds timing, and pharmacist interaction call.